Semaglutide and tirzepatide dont interact with each other, and your body doesnt need time to clear one before starting the other
You should consider speaking to your GP if you experience: Recurrent episodes of eating large amounts of food rapidly, at least once a week over three months A persistent sense of loss of control during eating episodes Significant distress, guilt, or shame following binges Eating in secret or hiding food Physical symptoms such as abdominal pain, fatigue, or unexplained weight changes Low mood, anxiety, or poor self-esteem linked to eating behaviour Your GP can carry out an initial assessment and refer you to appropriate services, which may include NHS Talking Therapies (formerly IAPT), a community eating disorder team, or a specialist eating disorder service depending on severity
Rybelsus is manufactured by Novo Nordisk and is produced under WHO-GMP-regulated pharmaceutical quality standards
Tirzepatide (Mounjaro) a dual GLP-1/GIP agonist licensed in the UK for type 2 diabetes and, following a positive NICE technology appraisal (TA1026), recommended for weight management in eligible adults within specialist services
Exosomes derived from eutopic and ectopic endometrial cells in endometriosis patients exhibit altered profiles of miRNAs (miR-22-3p, miR-320a, miR-17, miR-106a), lncRNAs (LINC00998, NEAT1, PVT1), and circRNAs
The terminals of myenteric intrinsic primary afferent neurons of the guinea-pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptors
